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Abstract
The forkhead box transcription factor FoxP3 controls the development and function of 
CD4+CD25+ regulatory T (Treg) cell. FoxP3 modulates gene expression in Treg cells by multiple 
epigenetic mechanisms that are not clearly defined. We identified FoxP3 interacting proteins in 
human T cells by co-IP/MS. We discovered that FoxP3 interacted with linker histone H1.5 via the 
leucine zipper (LZ) domain. Two independent IPEX patient-derived single residue mutations in 
the LZ of FoxP3 both abrogated its interaction with H1.5. Functionally, FoxP3 and H1.5 
cooperatively repressed IL-2 expression in human T cells; and silencing of H1.5 expression 
inhibited the ability of FoxP3 to suppress IL-2 expression. We show that FoxP3 specifically 
enhanced H1.5 association at the IL-2 promoter, but reduce its association at the CTLA4 
promoter, correlated with higher or lower histone acetylation of the respective promoters. Finally, 
silencing of H1.5 expression in human Treg cells impaired the Treg function to suppress target T 
cells. We conclude that FoxP3 interacts with H1.5 to alter its binding to target genes to modulate 
their expression and to program Treg function.
Introduction
Regulatory T (Treg) cells are required for the maintenance of self tolerance. The forkhead 
box transcription factor FoxP3 has been shown to be necessary for the Treg cell function. 
Scurfy mice deficient in FoxP3 function do not have CD4+CD25+ regulatory T cells and 
develop severe autoimmune lymphoproliferative disease1,2. Mutations in the foxp3 gene in 
humans also lead to immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
(IPEX) syndrome, characterized by multi-organ T cell infiltration and aggressive 
autoimmunity3,4. Furthermore, ectopic expression of FoxP3 confers a suppressive phenotype 
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to CD4+CD25− T cells, characterized by decreased cytokine (IL-2, IL-4 and IFN-γ) 
production and ability to suppress proliferation of other T cells5-7.
FoxP3 is a member of the P subfamily of the forkhead (FKH) box transcription factors, 
which are characterized by a highly conserved winged-helix/FKH DNA binding domain8. 
The FoxP3 protein includes an N-terminal proline-rich (PRR) domain, a C2H2 zinc finger, a 
leucine zipper (LZ), and a C-terminal FKH DNA binding domain. The PRR domain of 
FoxP3 has been shown to be able to repress transcription by recruiting histone deacetylase 
containing complexes9,10. Mutations identified from IPEX patients within the FoxP3 gene 
show clusters of missense or in-frame deletion mutations within the leucine zipper and FKH 
domains, indicating the importance of these domains for FoxP3 function11. The leucine 
zipper region of FoxP3 is required for the function of FoxP3, as demonstrated by two 
independent mutations within the leucine zipper (Δ250K & Δ251E) derived from IPEX 
patients12. The FKH domain of FoxP3 has been shown to bind DNA and mediate repression 
of the IL-2 promoter in Treg cells13.
While IL-2 is important for Treg cell development and survival, Treg cells themselves do 
not produce IL-2 in response to TCR stimulation14,15. The repression of IL-2 in Treg cells 
has been linked directly to FoxP3 through several different mechanisms. FoxP3 has been 
proposed to bind NFAT and displace AP-1 binding, thereby inhibiting the transactivation of 
IL-2 by NFAT/AP113. Furthermore, FoxP3 is also shown to interact with the transcription 
factor AML1/Runx1 to lead to IL-2 repression and Treg suppressive function16. 
Additionally, FoxP3 interactions with chromatin remodeling complexes containing histone 
deacetylases have been implicated in IL-2 repression and Treg function9.
Linker histone H1 proteins have long been known to play an important role in the assembly 
of hetero-chromatin filaments associated with gene silencing. In mice and humans, 5 highly 
homologous linker histone isoforms (H1a to H1e or H1.1 to H1.5) have been identified, 
which are differentially regulated during development17. While histone H1 depletion alters 
global chromatin structure, it surprisingly affects expression of only a few specific genes18. 
Mice with mutations in individual histone H1a, H1c, H1d, and H1e genes have been 
generated, with only subtle phenotypes19. Mice with triple mutations in H1c, H1d, and H1e 
genes are embryonic lethal and also show defects in expression and DNA methylation of 
only a few specific genes20. Thus, specific histone H1 isoforms may function in 
coordination with tissue specific transcription factors to regulate specific genes during 
development and differentiation. Indeed, murine histone H1b is involved in cooperation with 
the muscle specific transcription repressor Msx1 to repress MyoD expression and muscle 
differentiation21.
We report here that the human linker histone H1.5 specifically binded FoxP3. The physical 
association of H1.5 with FoxP3 required the leucine zipper domain of FoxP3. Two 
independent IPEX patient derived FoxP3 mutants of single residues in the LZ of FoxP3 also 
abrogated its interaction with H1.5. We show that ectopic expression of FoxP3 and H1.5 
synergistically repressed expression of IL-2 in human T cells, associated with chromatin 
modifications. Conversely, silencing of H1.5 expression in human T cells abrogated the 
ability of FoxP3 to repress IL-2 expression. FoxP3 interacted with H1.5 to specifically 
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enhance its association at the IL-2 promoter, but reduce its association at the CTLA4 
promoter, correlated with higher or lower acetylation of the respective promoters. Finally, 
silencing of H1.5 expression in human Treg cells impaired the Treg function to suppress 
target T cells. These findings suggest that interaction of linker histone H1.5 with FoxP3 
plays an important role in FoxP3-mediated gene expression and in maintaining Treg cell 
functions by FoxP3.
RESULTS
FoxP3 Interacts Specifically with Linker Histone H1.5
To investigate the molecular mechanisms by which FoxP3 functions in regulatory T cells, 
and to identify proteins that bind FoxP3, we expressed FoxP3 in a human CD4+ T cell line 
(Jurkat) with a retroviral vector. As expected, expression of FoxP3 in Jurkat cells inhibited 
IL-2 expression from the IL2 promoter following activation (Fig.S1). To search for FoxP3 
interacting proteins in these cell, we performed immunoprecipitation (IP) with an antibody 
specific for FoxP3 22. Clarified lysates from Jurkat cells were IPed with an anti-FoxP3 
antibody and resolved on an SDS−PAGE gel. Pre-blocking of the FoxP3 antibody with the 
specific FoxP3 peptide was used to identify specific FoxP3-interacting proteins that were 
pulled down by the IPed FoxP3 protein (Fig. 1A). Mass spectrometry revealed that one 
major FoxP3-associated protein was human linker histone H1.5, with a protein identification 
score of 269 and a total ion score of 169. The interaction was confirmed by co-IP, with 
either anti-FoxP3 or anti-H1.5 antibody, of coexpressed FoxP3 and H1.5 in 293 cells (Fig. 
1B). In order to determine the specificity of the interaction of FoxP3 with H1.5, we 
performed co-immunoprecipitation of H1a, H1.5 (or H1b), or H1e proteins with FoxP3 (Fig. 
1C). Only H1.5 was able to interact with FoxP3, suggesting that H1.5 may specifically play 
a role in the function of FoxP3 in programming regulatory T cells.
To delineate the domain of FoxP3 required for binding to H1.5, we performed co-IP of H1.5 
with truncated mutants of FoxP3 (Fig. 2A). The N-terminus domains including PRR and the 
zinc finger regions of FoxP3 were dispensable for binding to H1.5, as the ΔN and ΔN-ZF 
FoxP3 proteins were able to interact with H1.5 (Fig. 2B). The FoxP3 C-terminus region 
containing the forkhead DNA binding domain (Fkh) was not sufficient for the interaction 
with H1.5, suggesting that the leucine zipper of FoxP3 is critical for the interaction. 
Importantly, two independent IPEX patients-derived mutations of a single amino acid 
deletion within the leucine zipper region of FoxP3 (del-251E or del-250K) abrogated FoxP3 
binding to histone H1.5 (Fig. 2C). However, IPEX mutations in the FKH domain that 
abrogate FoxP3 binding to DNA did not alter the ability of FoxP3 to bind to H1.5 (data not 
shown). Therefore, the interaction between FoxP3 and H1.5 does not require DNA binding 
by FoxP3, but requires critical residues in the LZ domain that are correlated with the 
biological activity of FoxP3.
FoxP3 and H1.5 functionally interact to repress IL2 expression in human T cells
In order to determine the functional interaction of H1.5 and FoxP3, H1.5 and FoxP3 were 
ectopically expressed by retroviral transduction in Jurkat T cells. Co-expression of FoxP3 
and H1.5 did not affect their relative expression (Fig. 3A, inset). The Jurkat T cells were 
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stimulated and IL-2 expression was measured by IL-2 ELISA. Expression of FoxP3 alone in 
Jurkat T cells resulted in a 5-fold repression of IL-2 expression, while H1.5 expression alone 
caused low but not significant repression of IL-2 expression (Fig. 3A). Interestingly, co-
expression of FoxP3 and H1.5 led to a 45-fold repression of IL-2 expression (Fig. 3B). 
When the chromatin structure at the IL2 locus was analyzed, we confirmed that histone 
acetylation was partially reduced by FoxP3 expression, but completely repressed by FoxP3/
H1.5 coexpression. In addition, the relative trimethylation of H3 at K4, K9 and K27 
positions was also differentially modulated by FoxP3 and H1.5 (Fig. 3C). Thus FoxP3 and 
H1.5 interact to cooperatively suppress IL-2 gene expression via epigenetic mechanisms in 
human T cells.
To genetically prove the role of H1.5 in FoxP3-mediated suppression of IL-2 gene 
expression, we silenced expression of endogenous H1.5 gene and tested its effect on FoxP3's 
ability to repress IL-2 expression in T cells. The H1.5 shRNA construct was able to reduce 
expression of the flag-tagged H1.5 by 75% in co-transfected cells (Fig. 4A, inset). Human 
primary CD4+ T cells were co-transfected with a non-specific shRNA or an H1.5 specific 
shRNA plasmid in combination with either a control vector or a FoxP3 expression vector. 
The transfected cells were activated with anti-CD3/CD28, and IL-2 expression was 
measured by ELISA. Silencing of H1.5 expression by shRNA alone did not significantly 
affect IL-2 production. However, the activity of FoxP3 to repress IL-2 expression was 
severely impaired in CD4+ T cells with reduced expression of H1.5 (Fig. 4). When the IL2 
promoter (-226 to + 45)-luciferase gene was co-transfected with FoxP3 and H1.5 (Fig. S2A) 
or with FoxP3 and shRNA-H1.5 (Fig. S2B), similar inhibition results by FoxP3 and H1.5 as 
the endogenous IL2 gene were observed. Thus, FoxP3 requires H1.5 to repress IL-2 
expression in human CD4+ T cells.
FoxP3 modulates H1.5 association at the IL-2 and the CTLA4 promoters
In order to determine whether FoxP3 alters the binding of H1.5 at the FoxP3 target genes in 
human T cells, we performed Chromatin ImmunoPrecipitation (ChIP) analysis of flag-
tagged H1.5 and FoxP3 in human T cells. FoxP3 binds to the IL-2 proximal promoter in 
Jurkat T cells with or without exogenously expressed H1.5 (data not shown and 13). We 
show that binding of H1.5 at the IL-2 promoter was increased when FoxP3 was expressed in 
both unstimulated and stimulated Jurkat T cells (Fig. 5A and data not shown). When the 
IPEX patient-derived FoxP3 mutant (del-251E), which abrogated FoxP3 binding to H1.5 
(Fig. 2C), was tested by ChIP, it also failed to enhance binding of H1.5 to the IL-2 promoter 
(Fig. 5A). This increase in FoxP3-mediated H1.5 binding is associated with the repression of 
IL-2 gene expression and with reduced histone acetylation level of the IL-2 promoter (Fig. 
5B and DH-JBC). When the FoxP3-enhanced CTLA4 gene was analyzed, FoxP3 
significantly reduced the H1.5 association at the CTLA4 promoter (Fig. 5C), consistent with 
its enhanced expression and elevated histone acetylation level (Fig. 5D). In sum, our data 
support a model that FoxP3 modulates gene expression in T cells by modulating H1.5 
binding at distinct target promoters.
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H1.5, similar to FoxP3, is required for the suppression activity of Treg cells
The human CD4+ T cell subset (CD4+ CD45RA+CD25+) with Treg cell potential (TNreg) 
has been recently reported to become fully functional Treg cells after activation and 
expansion, with further induction of FoxP3 expression and suppression activity 23. To 
demonstrate that H1.5 is critical in the FoxP3-induced maturation of Treg cells with 
suppression activity, we investigated the effect of silencing endogenous H1.5 expression in 
human TNreg cells on their ability to suppress proliferation of CD4 T cells. Human TNreg 
cells were purified (>99% by FACS) and transduced with GFP-lentiviral vectors expressing 
non-specific shRNA (control), FoxP3-shRNA or H1.5-shRNA. The TNreg cells were then 
activated with monocyte derived dendritic cells (mDC) pulsed with Staphylococcal 
Enterotoxin B (SEB), and expanded to derive mature Treg cells 23. Transduced GFP+ Treg 
cells were then purified and used as Treg effectors in the suppression assay with 
CD4+CD25- T cells labeled with PKH26 as target cells. Proliferation of the target cells was 
examined by measuring PKH26 dilution at 4 or 5 days post stimulation (Fig. 6). Treg cells 
transduced with control shRNA vector efficiently suppressed target cell proliferation. 
Silencing of FoxP3 expression in Treg cells significantly reduced the suppression activity of 
Treg cells as recently reported 23. When expression of H1.5 was silenced in Treg cells, the 
suppression activity of Treg cells was also similarly reduced. Therefore, H1.5 is required for 
the FoxP3-induced suppression activity in Treg cells.
DISCUSSION
In this study we demonstrate a novel mechanism by which FoxP3 modulates gene 
expression in regulatory T cells. FoxP3 specifically interacted with the linker histone H1.5. 
Co-expression of H1.5 and FoxP3 lead to synergistic repression of IL-2 expression in human 
T cells. Conversely, knockdown of H1.5 expression in human T cells inhibited the ability of 
FoxP3 to repress IL-2 expression. In addition, FoxP3 interacted with H1.5 to specifically 
enhance its association at the IL-2 promoter, but reduce its association at the CTLA4 
promoter, correlated with higher or lower histone acetylation of the respective promoters. 
Finally, knockdown of either FoxP3 or H1.5 expression in human TNreg cells inhibited the 
ability of Treg cells to suppress target T cells, indicating that the interaction between FoxP3 
and linker histone H1.5 is important for FoxP3 function in human regulatory T cells.
The FoxP3-H1.5 interaction required the leucine zipper domain of FoxP3, suggesting that 
dimerization of FoxP3 with itself or other proteins may be necessary for H1.5 binding. 
Importantly, the human IPEX mutations with the 251E or the 250K amino acid deletion in 
the LZ region also both impaired its binding to H1.5, suggesting that H1.5 binding by FoxP3 
plays an important role in FoxP3 function. It has been reported that region of FoxP3 
between the leucine zipper and forkhead domain (AA278-336) is critical for binding to the 
transcription factor RUNX/AML116. It is possible that interaction with RUNX/AML1 may 
affect FoxP3 binding with H1.5, but it is not clear if the 251E or the 250K FoxP3 mutant is 
still able to bind RUNX/AML1. While previous studies have shown that the FoxP2/3 
forkhead domain binds DNA and interacts with NFAT13, our studies demonstrated that the 
FoxP3 DNA binding activity is not required for the physical interaction with H1.5, as shown 
with the IPEX mutations within the forkhead region of FoxP3 (Fig. S2). However, it is clear 
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that this FoxP3-H1.5 interaction is critical for IL-2 repression by FoxP3 and likely may 
modulate the expression of a group of target genes that are modulated by FoxP3 in 
regulatory T cells24. It will be of interest to identify genes/loci whose association with H1.5 
is modulated by FoxP3 in T cells.
We propose that FoxP3 binds to the IL-2 promoter and recruits H1.5, leading to its 
repression. Two independent IPEX patients-derived FoxP3 mutants with a single deletion in 
the LZ domain also failed to recruit H1.5 to the IL2 promoter, suggesting that the binding of 
FoxP3 with H1.5 may play a critical role in the FoxP3 activity to reprogram Treg cells. 
Interestingly, the muscle specific transcription repressor Msx1 also specifically interacts 
with murine H1b (homolog of human H1.5) to regulate mouse muscle cell differentiation. 
Msx1 binds and recruits H1b to the MyoD gene to repress its expression and muscle 
differentiation21. For target genes whose expression is enhanced by FoxP3 in Treg cells, 
FoxP3 reduced H1.5 binding to the CTLA4 promoter in activated T cells, via unclear 
mechanisms (Fig. 5C). Therefore, linker histone H1.5 plays a special role in modulating 
gene transcription in T cells through association with transcription factors such as FoxP3. 
However, the H1.5 association at the CD25 promoter was not altered by FoxP3. Instead, T 
cell activation significantly reduced H1.5 association at CD25 promoter (unpublished 
results). FoxP3 may therefore enhance target gene expression via multiple mechanisms.
While expression of H1.5/H1b decreases during differentiation in most tissues, H1.5/H1b 
expression is maintained at high levels in lymphocytes and lymphoid organs such as thymus 
and spleen25. It is likely that H1b is preferentially involved in lymphocyte differentiation 
and functions. To date, however, the H1b gene has not been knocked out in mice, which 
may prove to have a specific phenotype due to its expression and interactions with tissue 
specific transcription factors. On the other hand, mice with mutations in one or two of the 
linker H1 histone genes have developed normally, with no significant differences in the total 
H1-to-nucleosome core H2-4 histone stoichiometry, indicating that H1 subtypes are able to 
compensate for each other during mouse development18,19. It may be necessary to generate 
conditional mutant mice with inducible deletion of H1b gene in order to observe its effect in 
specific tissues or cell types.
FoxP3 has been recently described to be associated with a chromatin remodeling complex 
including TIP60, HDAC7, and members of the SWI/SNF family9,26. We describe here 
another mechanism of FoxP3 transcriptional modulation through modulation of linker 
histone H1.5 binding to alter the chromatin structure at FoxP3-responsive genes. Our results 
do not preclude the idea that FoxP3 may form a large complex with H1.5, other transcription 
factors, and chromatin remodeling complexes. Indeed, another human histone H1 isoform, 
H1.4, has recently been reported to specifically interact with the malignant brain tumor 
protein L3MBTL1 to compact chromatin and repress expression of E2F regulated genes27. 
FoxP3 may similarly alter the chromatin structures at distinct gene loci to coordinate Treg 
maturation and functions. Additionally, the reciprocal binding of PARP-1 and Histone H1 
has been shown to affect gene expression outcomes28. Thus, it is likely that the combination 
of these factors is required for FoxP3 function. Different classes of FoxP3 regulated genes 
may use different combinations of mechanisms to specifically up- or down-modulate their 
expression during Treg development or in response to Treg activation. Our findings on the 
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functional interaction of FoxP3 with linker histone H1.5 have important implications in 
understanding the transcriptional program of Treg cells. The findings will also help to 
elucidate how linker histones modulate expression of specific genes through interactions 
with specific transcription factors. Finally, as single residues in the LZ domain of FoxP3 are 
critical for H1.5 binding and FoxP3 function, the interaction between FoxP3 and H1.5 may 
provide a novel target to modulate Treg development and functions.
Materials and Methods
Plasmids, antibodies, and cell lines
FoxP3 was expressed from the HSPG retrovirus vector 29. Deletion mutants of FoxP3 were 
generated by PCR amplification to specifically remove the N-terminus (aa 1-189), the N-
terminus with the Zinc finger motif (aa1-241), the N-terminus including the zinc finger and 
the leucine zipper (aa 1-337). Human H1.5 was PCR amplified from genomic Jurkat cell 
DNA and cloned into the pHITflag vector. pcDNA-V5-H1a and pcDNA-HA-H1d were 
generous gifts from Dr. Corey Abate-Shen21. The Δ251E and Δ250K point mutants were 
introduced into FoxP3 by site-directed mutagenesis and verified by DNA sequencing. The 
NS shRNA plasmid (pLL5.0NS) was a kind gift from Dr. Jim Bear30. The non-specific 
shRNA was generated by using the target loop sequence GATCGACTTACGACGTTAT. 
The H1.5 shRNA was purchased from Open Biosystems in the pGINZeo vector, using the 
H1.5 target loop sequence TAGTGAAGCCACAGATGTA. Jurkat cells were maintained in 
RPMI 1640 (Gibco BRL), 293T cells were maintained in DMEM and human primary T 
cells were maintained in Iscoves MEM, supplemented with 10% FBS (Sigma), 2mM L-
glutamine, 100U/ml penicillin, 100U/ml streptomycin. For T cell activation, PMA (Sigma, 
25ng/ml) and ionomycin (Sigma, 1uM), mouse anti-CD3 mouse, anti-CD28 (BD 
Biosciences), and goat anti-mouse IgG (Caltag) were used. FoxP3 antibodies have been 
previously described22. The peptide from the N-terminus of murine FoxP3 
(CLLGTRGSGGPFQGRDLRSGAH) was used to immunize rabbits for production of 
polyclonal antibodies. Affinity purification of the antibodies was performed with a 
SulfoLink Kit (Pierce Biotechology, Rockford, IL). The mouse anti-myc (9E10) monoclonal 
supernatant was kindly provided by Dr. Y. Xiong (UNC, NC). The mouse anti-Flag M2 
(Sigma) and the rabbit anti-histone H1.5 from Abcam were used.
Retrovirus and lentiviral vector production and transduction
293T cells were cotransfected with retroviral vector, VSV-g, and Gag-Pol containing 
plasmids by calcium phosphate, as previously described29. For retroviral transduction, 
Jurkat cells were spinoculated with retrovirus to >90% efficiency as measured by GFP 
expression31. For VSV-g pseudotyped HIV-derived lentiviral vector production, 293T cells 
were transfected with Effectene (Qiagen) transfection reagent per manufacturer's 
instructions. 48 hour post transfection supernatants were used to infect Jurkat cells by 
spinoculation.
Immunoprecipitations
Whole cell extracts were made from FoxP3 transduced Jurkat cells using modified RIPA 
extraction buffer. Extracts (40mg) were immunoprecipitated using affinity purified anti-
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FoxP3 (Li195) antibodies in PBS, 10uM NaVO4 , 10uM DTT, 1uM PMSF, and 1X protease 
inhibitor cocktail (Roche). FoxP3 antibodies were pre-incubated for 1h with the Li195 
peptide, prior to immunoprecipitation for the peptide specificity control. Immune complexes 
were precipitated by addition of Protein A agarose beads (Pierce). Complexes were eluted 
by boiling in SDS-loading dye buffer, resolved by SDS-PAGE and visualized with 
Coomassie Brilliant Blue stain. Protein bands were cut from the gel and sequence analysis 
was performed by the UNC Proteomics Core Facility by reverse phase HPLC tandem mass 
spectrometry (LC/MS). Co-immunoprecipitation experiments were performed using nuclear 
extracts of 293T cells transfected (Effectene, Qiagen) with flag-tagged H1b and myc-
tagged-FoxP3, using either mouse anti-myc (9E10) hybridoma supernantant or mouse anti-
flag M2 (Sigma) antibodies. Proteins were analyzed by immunoblotting and detection with 
ECL plus western blotting detection (Amersham).
Chromatin immunoprecipitation assays (ChIPs)
Jurkat T cells were retrovirallytransduced with control or flag-H1b expressing virus, 
followed by a second transduction 48h later with control or FoxP3 expressing virus. 
Sonicated chromatin from the Jurkat cells was immunoprecipitated with control IgG (IgG) 
or anti-myc (9E10) (Santa Cruz Biotechnologies) or anti-flagM2 (Sigma) by chromatin 
immunoprecipitation assay kit perthe manufacturer's instruction (Upstate, Millipore), as 
previously reported31. Sampleswere purified and subject to real-time qPCR analysis. IL-2 
promoter was analyzed withSybergreen reagents using the following primers: 5’-CAC CTA 
AGT GTG TGG GCT AAT GTA AC-3’ and 5’-CTG ATG ACT CTT TGG AAT TTC TTT 
AAA CC-3’. This amplicon spans –226 to –133 in the human IL-2 promoter and spans the 
NFκB and AP-1 sites. The relative mycFP3 or flagH1b binding of IL-2 promoter is 
expressed with ratios of ChIP-specific signal divided by signals from control 10% input 
chromatins, then normalized to non-specific IgG antibody binding.
Primary human T-cell purification and transfection
CD4+ primary T cells were purified from Ficoll-separated PBMC (peripheral blood 
mononuclear cell) by MACS human CD4+ T-cell isolation kit (>90% purity, Miltenyi-
Biotech, Auburn, CA). Purified primary CD4+ T cells were transfected by using the Amaxa 
nucleofector kit (Amaxa Biosystems, Gaithersburg, MD). Briefly, 10 × 106 unstimulated 
CD4+ T cells were transfected with 2 μg of plasmid DNA (~50% efficiency by GFP 
expression), and cultured for 24h before activation.
IL-2 ELISA
Jurkat T cells were activated by PMA (25ng/ml) and ionomycin (1uM) for 16h. Media 
supernatants were harvested and analyzed by the human IL-2 ELISA kit (BD Biosciences), 
as per manufacturer's instructions. Primary CD4+ T cells were activated by anti-CD3/CD28 
monoclonal antibody cross-linked by plate-bound anti-mouse IgG as previously described. 
Briefly, purified cells are stained with anti-CD3 (0.5 μg/ml) and anti-CD28 (2 μg/ml) and 
incubated on plated-bound goat anti-mouse IgG. Cells were activated for 72h, and media 
supernatants were harvested for IL-2 ELISA. Four independent experiments (each in 
triplicates) are carried out.
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Isolation, expansion and lentiviral transduction of TNreg cells
were performed as recently reported23. Briefly, naive and TNreg cells were sorted from 
human blood as described before23. Cells were activated with monocyte derived dentric 
cells (DC) and Staphylococcal Enterotoxin B (SEB), and grown for 5 days before infected 
by shRNA expressing virus supernatant. Preparation of the control and Foxp3 shRNA 
viruses has been described23. Cells were then expanded for another week, sorted based on 
GFP expression and GFP+ cells were used as effectors in a suppression assay.
Treg suppression assay
Naive CD4+ T cells were labeled with PKH26 (Invitrogen), and used as target cells. Target 
cells and different effector cells were mixed at a ratio 1:4 or 1:8, and stimulated with DC 
(1:30) and SEB (10~0.1pg/ml). Proliferation of the target cells were examined 4 or 5 days 
post stimulation23.
Statistical Analysis
For statistical analysis, a two-tailed Student t test is employed where p < 0.05 is considered 
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. FoxP3 specifically interacts with linker histone H1.5
(A) Cell extracts from Jurkat cells expressing FoxP3 (2-5x10e8 cells) were immuno-
precipitated with anti-FoxP3 antibodies or anti-FoxP3 antibodies pre-blocked with the 
antigen peptide. Proteins were resolved by SDS-PAGE and visualized by Coomassie blue 
staining of the gel. Positions of molecular weight markers are shown in kilodaltons (kd). The 
major bands that are specifically pulled down were identified by Mass spectrometry (MS). 
The peptides identified by MS from one major band (all matched to human H1.5) are listed 
in the table. (B) Nuclear extracts from 293T cells transfected with myc-FoxP3 and/or flag-
H1.5 were immunoprecipitated with anti-myc or anti-flag antibodies, and immuno-blotted 
with the indicated antibodies. (C) Specificity of H1.5 binding to FoxP3. Nuclear extracts 
from 293T cells transfected with three different tagged-histone H1 isoforms (V5-H1a, Flag-
H1.5, HA-H1e) and myc-FoxP3 were immunoprecipitated with the indicated antibodies and 
interactions were detected by immunoblotting. 10% inputs of the extract used for IPs are 
shown in the lower panels.
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FIGURE 2. FoxP3 specifically interacts with linker histone H1.5 via critical residues in the 
leucine zipper domain
(A) Diagrams of the FoxP3 protein domain structure and deletion mutants31. FL=full length, 
ΔN=N-terminus deletion, ΔN-ZF= deleted N-terminus and zinc finger, Fkh=deleted N-
terminus, zinc finger, and leucine zipper. Δ250K/Δ251E=mutant FoxP3 alleles isolated from 
IPEX patients. (B) Nuclear extracts from 293T cells transfected with flagH1.5 and 
mycFoxP3 deletion mutants were IPed with anti-flag antibodies and co-IPed mycFoxP3 
proteins were detected by immunoblotting. (C) The amino acid residues 250K/251E in 
leucine zipper domain of FoxP3 are both critical for binding to H1.5, as well as for FoxP3 
function. Nuclear extracts from 293T cells transfected with flagH1.5 and human FoxP3 
(lane 1), Δ250K (lane 2) or Δ251E (lane 3), the Forkhead domain (lane 4), FoxP3 only (lane 
5), and flagH1.5 only (lane 6). Flag-H1.5 was immuno-precipitated with anti-flag antibodies 
and Western blotted with the indicated antibodies. Inputs represent 5% of cell lysates used 
for each co-IP experiment.
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FIGURE 3. FoxP3 and H1.5 interact functionally to repress IL2 gene expression in T cells
(A-B) FoxP3 and H1.5 cooperate to synergistically repress IL-2 expression in human T 
cells. (A) Jurkat T cells stably expressing flag-H1.5 were re-transduced with control vector 
or FoxP3-expressing vector (>95% with each or both vectors). Inset shows Western blot of 
FoxP3 and flagH1.5 expression. Transduced cells were stimulated with PMA and 
Ionomycin, and IL-2 expression was measured by IL-2 ELISA in culture supernatants in 
triplicates. Shown are IL2 levels normalized to total live cell numbers in each sample. Error 
bars indicate standard deviation. (B) Summary of relative repression of IL-2 from four 
independent experiments. Error bars indicate standard error, p-values are determined by 
two-tailed students’ t-test. *, p<0.05, **, P<0.005. (C) ChIP assays were performed to assess 
histone modifications (Acetylation of H3/H4, tri-methylation of H3 K4, K9 and K27) at the 
IL2 promoter. Results are quantified by real-time PCR and normalized to binding by control 
IgG antibody. Error bars indicate standard deviation. * = p<0.05.
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FIGURE 4. H1.5 is required for FoxP3-mediated IL-2 repression in human T cells
(A) Expression of H1.5 is specifically knocked down by the H1.5 shRNA construct. H1.5 
levels are determined by Western blot analysis of flag-H1.5 in 293T cells cotransfected with 
NS (non-specific) or H1.5-specific shRNA vector. Relative H1.5 expression normalized to 
tubulin protein is shown under the panels (inset). Primary human CD4+ T cells were 
transfected by Amaxa nucleofection with either the control NS-shRNA or H1.5-specific 
shRNA plasmids with or without FoxP3. Cells in triplicate wells were stimulated with anti-
CD3 and anti-CD28 antibody for 48h and culture supernatants were analyzed by IL-2 
ELISA. Error bars indicate standard deviation. (B) Relative repression (fold) of IL-2 in 
primary CD4+ T cells from two independent experiments is summarized. * = p<0.05, ** = 
p<0.005.
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FIGURE 5. FoxP3 specifically modulates H1.5 association and histone modification at the IL-2 
or CTLA4 promoter
Jurkat T cells stably expressing flag-H1.5 were transduced with control vector or FoxP3-
expressing vector. ChIP assays were performed with anti-flag antibody to assess H1.5 
binding to the target promoters. The distal region of IL-2 gene showed only background 
binding (data not shown). ChIP assay was also performed with anti-AcH3/4 mAb to 
measure relative acetylation of histones H3 andH4 at the target promoters. Results are 
quantified by real-time PCR and normalized to binding by control IgG antibody. Error bars 
indicate standard deviation. * = p<0.05, **=p<0.01. (A) αFlagH1.5 ChIP at the IL-2 
promoter in FlagH1.5-Jurkat cells transduced with wild type or del-251E IPEX mutant 
FoxP3. (B) Relative acetylation of the IL2 promoter was measured by anti-AcH3/4 ChIP. 
(C) αFlagH1.5 ChIP at the CTLA4 promoter in FlagH1.5-Jurkat cells transduced with 
control vector or FoxP3. Both un-stimulated and activated cells were analyzed by ChIP. (D) 
Relative acetylation of the CTLA4 promoter was measured by anti-AcH3/4 ChIP.
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FIGURE 6. H1.5 is required for FoxP3-induced Treg suppression activity
CD4+CD25+CD45RA+ (TNreg) cells were sorted from human blood (>99% purity), 
activated with SEB-pulsed DC, and transduced with shRNA expressing lentiviral-GFP 
vectors. Cells were then expanded, and sorted based on GFP expression. Transduced GFP+ 
cells were used as Treg effectors in a suppression assay, with CD4+CD25- T cells labeled 
with PKH26 as target cells. Treg cells and target cells were mixed at 1:8, and stimulated 
with mDC (1:30) pulsed with SEB (1 pg/ml). Proliferation of the target cells were examined 
4 (top) or 5 (bottom) days post stimulation. Numbers indicate relative proliferation (PKH26 
dilution). Similar results are observed from two independent experiments at multiple 
conditions.
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